In the context of drug development, two signaling axes have predominantly underpinned modern therapeutic strategies in HCC: the PI3K/AKT/mTOR pathway—targeted by mTOR/PI3K inhibitors or rational combinations—and the Wnt/β-catenin pathway, which shapes tumor biology and immune exclusion and is being explored for indirect therapeutic modulation. This evidence concerns the gene MTOR and neoplasm.